Genetic Characterization and Enhanced Surveillance of Ceftriaxone-Resistant Neisseria gonorrhoeae Strain, Alberta, Canada, 2018

Emerg Infect Dis. 2019 Sep;25(9):1660-1667. doi: 10.3201/eid2509.190407. Epub 2019 Sep 17.

Abstract

In July 2018, a case of Neisseria gonorrhoeae associated with ceftriaxone treatment failure was identified in Alberta, Canada. We identified the isolate and nucleic acid amplification testing (NAAT) specimen as the ceftriaxone-resistant strain multilocus sequence type 1903/NG-MAST 3435/NG-STAR 233, originally identified in Japan (FC428), with the same penA 60.001 mosaic allele and genetic resistance determinants. Core single-nucleotide variant (SNV) analysis identified 13 SNVs between this isolate and FC428. Culture-independent surveillance by PCR for the A311V mutation in the penA allele and N. gonorrhoeae multiantigen sequence typing directly from NAAT transport media positive for N. gonorrhoeae by NAAT did not detect spread of the strain. We identified multiple sequence types not previously detected in Alberta by routine surveillance. This case demonstrates the benefit of using culture-independent methods to enhance detection, public health investigations, and surveillance to address this global threat.

Keywords: Alberta; Canada; Neisseria gonorrhoeae; antimicrobial resistance; azithromycin; bacteria; cefixime; ceftriaxone; cephalosporin; drug resistance; gonorrhea; molecular epidemiology; molecular typing; penicillin binding protein 2; treatment failure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alberta / epidemiology
  • Anti-Bacterial Agents / pharmacology*
  • Cephalosporin Resistance / genetics*
  • Gonorrhea / epidemiology*
  • Gonorrhea / microbiology
  • Humans
  • Microbial Sensitivity Tests
  • Neisseria gonorrhoeae / drug effects
  • Neisseria gonorrhoeae / genetics
  • Neisseria gonorrhoeae / isolation & purification*
  • Phylogeny
  • Polymerase Chain Reaction
  • Population Surveillance

Substances

  • Anti-Bacterial Agents